APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Nanomaterial-Based Adjuvants Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Nanomaterial-Based Adjuvants Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025185 pages

Choose your research edition.

Industry ResearchNanomaterial-Based Adjuvants Vaccine Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Nanomaterial-Based Adjuvants Vaccine Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal Nanomaterial-Based Adjuvants Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Nanomaterial-Based Adjuvants Vaccine Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Nanomaterial-Based Adjuvants Vaccine Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Nanomaterial-Based Adjuvants Vaccine market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Nanomaterial-Based Adjuvants Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Nanomaterial-Based Adjuvants Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Nanomaterial-Based Adjuvants Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Nanomaterial-Based Adjuvants Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Nanomaterial-Based Adjuvants Vaccine include Emergent BioSolutions, GlaxoSmithKline Biologicals, Moderna, Pfizer, Merck, Novartis, Jiangsu Recbio Technology and Sanofi, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Nanomaterial-Based Adjuvants Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Nanomaterial-Based Adjuvants Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Nanomaterial-Based Adjuvants Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Nanomaterial-Based Adjuvants Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Nanomaterial-Based Adjuvants Vaccine Segment by Company

Emergent BioSolutions

GlaxoSmithKline Biologicals

Moderna

Pfizer

Merck

Novartis

Jiangsu Recbio Technology

Sanofi

Nanomaterial-Based Adjuvants Vaccine Segment by Type

Lipidosome

Aluminium Hydroxides

Aluminium Phosphate

Others

Nanomaterial-Based Adjuvants Vaccine Segment by Application

DTaP

Pneumococcus

Viral Hepatitis TypeA

Human Papilloma Virus

SARS-CoV-2

Viral Hepatitis TypeB

Others

Nanomaterial-Based Adjuvants Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nanomaterial-Based Adjuvants Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Nanomaterial-Based Adjuvants Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nanomaterial-Based Adjuvants Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Nanomaterial-Based Adjuvants Vaccine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Nanomaterial-Based Adjuvants Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Nanomaterial-Based Adjuvants Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Nanomaterial-Based Adjuvants Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Nanomaterial-Based Adjuvants Vaccine Industry Trends Table 2. Nanomaterial-Based Adjuvants Vaccine Industry Drivers Table 3. Nanomaterial-Based Adjuvants Vaccine Industry Opportunities and Challenges Table 4. Nanomaterial-Based Adjuvants Vaccine Industry Restraints Table 5. Global Nanomaterial-Based Adjuvants Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Nanomaterial-Based Adjuvants Vaccine Sales by Manufacturers (M Units) & (2021-2026) Table 8. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Manufacturers Table 9. Global Nanomaterial-Based Adjuvants Vaccine Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Nanomaterial-Based Adjuvants Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Nanomaterial-Based Adjuvants Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Nanomaterial-Based Adjuvants Vaccine Manufacturers, Product Type & Application Table 13. Global Nanomaterial-Based Adjuvants Vaccine Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Nanomaterial-Based Adjuvants Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Lipidosome Table 17. Major Manufacturers of Aluminium Hydroxides Table 18. Major Manufacturers of Aluminium Phosphate Table 19. Major Manufacturers of Others Table 20. Global Nanomaterial-Based Adjuvants Vaccine Sales by Type 2021 VS 2025 VS 2032 (M Units) Table 21. Global Nanomaterial-Based Adjuvants Vaccine Sales by Type (2021-2026) & (M Units) Table 22. Global Nanomaterial-Based Adjuvants Vaccine Sales by Type (2027-2032) & (M Units) Table 23. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Type (2021-2026) Table 24. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Type (2027-2032) Table 25. Global Nanomaterial-Based Adjuvants Vaccine Revenue by Type 2021 VS 2025 VS 2032 (M Units) Table 26. Global Nanomaterial-Based Adjuvants Vaccine Revenue by Type (2021-2026) & (M Units) Table 27. Global Nanomaterial-Based Adjuvants Vaccine Revenue by Type (2027-2032) & (M Units) Table 28. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Type (2021-2026) Table 29. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of DTaP Table 31. Major Manufacturers of Pneumococcus Table 32. Major Manufacturers of Viral Hepatitis TypeA Table 33. Major Manufacturers of Human Papilloma Virus Table 34. Major Manufacturers of SARS-CoV-2 Table 35. Major Manufacturers of Viral Hepatitis TypeB Table 36. Major Manufacturers of Others Table 37. Global Nanomaterial-Based Adjuvants Vaccine Sales by Application 2021 VS 2025 VS 2032 (M Units) Table 38. Global Nanomaterial-Based Adjuvants Vaccine Sales by Application (2021-2026) & (M Units) Table 39. Global Nanomaterial-Based Adjuvants Vaccine Sales by Application (2027-2032) & (M Units) Table 40. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Application (2021-2026) Table 41. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Application (2027-2032) Table 42. Global Nanomaterial-Based Adjuvants Vaccine Revenue by Application 2021 VS 2025 VS 2032 (M Units) Table 43. Global Nanomaterial-Based Adjuvants Vaccine Revenue by Application (2021-2026) & (M Units) Table 44. Global Nanomaterial-Based Adjuvants Vaccine Revenue by Application (2027-2032) & (M Units) Table 45. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Application (2021-2026) Table 46. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Application (2027-2032) Table 47. Global Nanomaterial-Based Adjuvants Vaccine Sales by Region: 2021 VS 2025 VS 2032 (M Units) Table 48. Global Nanomaterial-Based Adjuvants Vaccine Sales by Region (2021-2026) & (M Units) Table 49. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Region (2021-2026) Table 50. Global Nanomaterial-Based Adjuvants Vaccine Sales Forecasted by Region (2027-2032) & (M Units) Table 51. Global Nanomaterial-Based Adjuvants Vaccine Sales Forecasted Market Share by Region (2027-2032) Table 52. North America Nanomaterial-Based Adjuvants Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Units) Table 53. North America Nanomaterial-Based Adjuvants Vaccine Sales by Country (2021-2026) & (M Units) Table 54. North America Nanomaterial-Based Adjuvants Vaccine Sales by Country (2027-2032) & (M Units) Table 55. Europe Nanomaterial-Based Adjuvants Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Units) Table 56. Europe Nanomaterial-Based Adjuvants Vaccine Sales by Country (2021-2026) & (M Units) Table 57. Europe Nanomaterial-Based Adjuvants Vaccine Sales by Country (2027-2032) & (M Units) Table 58. Asia Pacific Nanomaterial-Based Adjuvants Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Units) Table 59. Asia Pacific Nanomaterial-Based Adjuvants Vaccine Sales by Country (2021-2026) & (M Units) Table 60. Asia Pacific Nanomaterial-Based Adjuvants Vaccine Sales by Country (2027-2032) & (M Units) Table 61. South America, Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (M Units) Table 62. South America, Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Sales by Country (2021-2026) & (M Units) Table 63. South America, Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Sales by Country (2027-2032) & (M Units) Table 64. Global Nanomaterial-Based Adjuvants Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 65. Global Nanomaterial-Based Adjuvants Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 66. Global Nanomaterial-Based Adjuvants Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 67. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Region (2021-2026) Table 68. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Region (2027-2032) Table 69. Emergent BioSolutions Company Information Table 70. Emergent BioSolutions Business Overview Table 71. Emergent BioSolutions Nanomaterial-Based Adjuvants Vaccine Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Emergent BioSolutions Nanomaterial-Based Adjuvants Vaccine Product Portfolio Table 73. Emergent BioSolutions Recent Development Table 74. GlaxoSmithKline Biologicals Company Information Table 75. GlaxoSmithKline Biologicals Business Overview Table 76. GlaxoSmithKline Biologicals Nanomaterial-Based Adjuvants Vaccine Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. GlaxoSmithKline Biologicals Nanomaterial-Based Adjuvants Vaccine Product Portfolio Table 78. GlaxoSmithKline Biologicals Recent Development Table 79. Moderna Company Information Table 80. Moderna Business Overview Table 81. Moderna Nanomaterial-Based Adjuvants Vaccine Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Moderna Nanomaterial-Based Adjuvants Vaccine Product Portfolio Table 83. Moderna Recent Development Table 84. Pfizer Company Information Table 85. Pfizer Business Overview Table 86. Pfizer Nanomaterial-Based Adjuvants Vaccine Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Pfizer Nanomaterial-Based Adjuvants Vaccine Product Portfolio Table 88. Pfizer Recent Development Table 89. Merck Company Information Table 90. Merck Business Overview Table 91. Merck Nanomaterial-Based Adjuvants Vaccine Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Merck Nanomaterial-Based Adjuvants Vaccine Product Portfolio Table 93. Merck Recent Development Table 94. Novartis Company Information Table 95. Novartis Business Overview Table 96. Novartis Nanomaterial-Based Adjuvants Vaccine Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Novartis Nanomaterial-Based Adjuvants Vaccine Product Portfolio Table 98. Novartis Recent Development Table 99. Jiangsu Recbio Technology Company Information Table 100. Jiangsu Recbio Technology Business Overview Table 101. Jiangsu Recbio Technology Nanomaterial-Based Adjuvants Vaccine Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Jiangsu Recbio Technology Nanomaterial-Based Adjuvants Vaccine Product Portfolio Table 103. Jiangsu Recbio Technology Recent Development Table 104. Sanofi Company Information Table 105. Sanofi Business Overview Table 106. Sanofi Nanomaterial-Based Adjuvants Vaccine Sales (M Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Sanofi Nanomaterial-Based Adjuvants Vaccine Product Portfolio Table 108. Sanofi Recent Development Table 109. Key Raw Materials Table 110. Raw Materials Key Suppliers Table 111. Nanomaterial-Based Adjuvants Vaccine Distributors List Table 112. Nanomaterial-Based Adjuvants Vaccine Customers List Table 113. Research Programs/Design for This Report Table 114. Authors List of This Report Table 115. Secondary Sources Table 116. Primary Sources List of Figures Figure 1. Nanomaterial-Based Adjuvants Vaccine Product Image Figure 2. Global Nanomaterial-Based Adjuvants Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Nanomaterial-Based Adjuvants Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global Nanomaterial-Based Adjuvants Vaccine Sales (2021-2032) & (M Units) Figure 5. Global Nanomaterial-Based Adjuvants Vaccine Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Nanomaterial-Based Adjuvants Vaccine Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Lipidosome Image Figure 9. Aluminium Hydroxides Image Figure 10. Aluminium Phosphate Image Figure 11. Others Image Figure 12. Global Nanomaterial-Based Adjuvants Vaccine Sales by Type (2021 VS 2025 VS 2032) & (M Units) Figure 13. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Type (2021-2032) Figure 15. Global Nanomaterial-Based Adjuvants Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (M Units) Figure 16. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Type (2021-2032) Figure 18. DTaP Image Figure 19. Pneumococcus Image Figure 20. Viral Hepatitis TypeA Image Figure 21. Human Papilloma Virus Image Figure 22. SARS-CoV-2 Image Figure 23. Viral Hepatitis TypeB Image Figure 24. Others Image Figure 25. Global Nanomaterial-Based Adjuvants Vaccine Sales by Application (2021 VS 2025 VS 2032) & (M Units) Figure 26. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share 2021 VS 2025 VS 2032 Figure 27. Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Application (2021-2032) Figure 28. Global Nanomaterial-Based Adjuvants Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (M Units) Figure 29. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 30. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Application (2021-2032) Figure 31. North America Nanomaterial-Based Adjuvants Vaccine Sales and Growth Rate (2021-2032) & (M Units) Figure 32. North America Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Country (2021-2032) Figure 33. U.S. Nanomaterial-Based Adjuvants Vaccine Sales and Growth Rate (2021-2032) & (M Units) Figure 34. Canada Nanomaterial-Based Adjuvants Vaccine Sales and Growth Rate (2021-2032) & (M Units) Figure 35. Mexico Nanomaterial-Based Adjuvants Vaccine Sales and Growth Rate (2021-2032) & (M Units) Figure 36. Europe Nanomaterial-Based Adjuvants Vaccine Sales and Growth Rate (2021-2032) & (M Units) Figure 37. Europe Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Country (2021-2032) Figure 38. Germany Nanomaterial-Based Adjuvants Vaccine Sales and Growth Rate (2021-2032) & (M Units) Figure 39. France Nanomaterial-Based Adjuvants Vaccine Sales and Growth Rate (2021-2032) & (M Units) Figure 40. U.K. Nanomaterial-Based Adjuvants Vaccine Sales and Growth Rate (2021-2032) & (M Units) Figure 41. Italy Nanomaterial-Based Adjuvants Vaccine Sales and Growth Rate (2021-2032) & (M Units) Figure 42. Netherlands Nanomaterial-Based Adjuvants Vaccine Sales and Growth Rate (2021-2032) & (M Units) Figure 43. Asia Pacific Nanomaterial-Based Adjuvants Vaccine Sales and Growth Rate (2021-2032) & (M Units) Figure 44. Asia Pacific Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Country (2021-2032) Figure 45. China Nanomaterial-Based Adjuvants Vaccine Sales and Growth Rate (2021-2032) & (M Units) Figure 46. Japan Nanomaterial-Based Adjuvants Vaccine Sales and Growth Rate (2021-2032) & (M Units) Figure 47. South Korea Nanomaterial-Based Adjuvants Vaccine Sales and Growth Rate (2021-2032) & (M Units) Figure 48. Southeast Asia Nanomaterial-Based Adjuvants Vaccine Sales and Growth Rate (2021-2032) & (M Units) Figure 49. India Nanomaterial-Based Adjuvants Vaccine Sales and Growth Rate (2021-2032) & (M Units) Figure 50. Australia Nanomaterial-Based Adjuvants Vaccine Sales and Growth Rate (2021-2032) & (M Units) Figure 51. South America, Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Sales and Growth Rate (2021-2032) & (M Units) Figure 52. South America, Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Country (2021-2032) Figure 53. Brazil Nanomaterial-Based Adjuvants Vaccine Sales and Growth Rate (2021-2032) & (M Units) Figure 54. South Africa Nanomaterial-Based Adjuvants Vaccine Sales and Growth Rate (2021-2032) & (M Units) Figure 55. Saudi Arabia Nanomaterial-Based Adjuvants Vaccine Sales and Growth Rate (2021-2032) & (M Units) Figure 56. Turkey Nanomaterial-Based Adjuvants Vaccine Sales and Growth Rate (2021-2032) & (M Units) Figure 57. Argentina Nanomaterial-Based Adjuvants Vaccine Sales and Growth Rate (2021-2032) & (M Units) Figure 58. UAE Nanomaterial-Based Adjuvants Vaccine Sales and Growth Rate (2021-2032) & (M Units) Figure 59. Egypt Nanomaterial-Based Adjuvants Vaccine Sales and Growth Rate (2021-2032) & (M Units) Figure 60. Chile Nanomaterial-Based Adjuvants Vaccine Sales and Growth Rate (2021-2032) & (M Units) Figure 61. Global Nanomaterial-Based Adjuvants Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 63. North America Nanomaterial-Based Adjuvants Vaccine Revenue (2021-2032) & (US$ Million) Figure 64. North America Nanomaterial-Based Adjuvants Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Europe Nanomaterial-Based Adjuvants Vaccine Revenue (2021-2032) & (US$ Million) Figure 66. Europe Nanomaterial-Based Adjuvants Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Revenue (2021-2032) & (US$ Million) Figure 68. Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. South America, Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Revenue (2021-2032) & (US$ Million) Figure 70. South America, Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 71. Nanomaterial-Based Adjuvants Vaccine Value Chain Figure 72. Manufacturing Cost Structure Figure 73. Nanomaterial-Based Adjuvants Vaccine Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Years Considered Figure 77. Research Process Figure 78. Key Executives Interviewed

Scope & coverage.

Types
  • Lipidosome
  • Aluminium Hydroxides
  • Aluminium Phosphate
  • Others
Applications
  • DTaP
  • Pneumococcus
  • Viral Hepatitis TypeA
  • Human Papilloma Virus
  • SARS-CoV-2
  • Viral Hepatitis TypeB
  • Others
Companies covered
  • Emergent BioSolutions
  • GlaxoSmithKline Biologicals
  • Moderna
  • Pfizer
  • Merck
  • Novartis
  • Jiangsu Recbio Technology
  • Sanofi

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Nanomaterial-Based Adjuvants Vaccine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Nanomaterial-Based Adjuvants Vaccine Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Nanomaterial-Based Adjuvants Vaccine Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Nanomaterial-Based Adjuvants Vaccine Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Nanomaterial-Based Adjuvants Vaccine Market Dynamics
  1. 2.1 Nanomaterial-Based Adjuvants Vaccine Industry Trends
  2. 2.2 Nanomaterial-Based Adjuvants Vaccine Industry Drivers
  3. 2.3 Nanomaterial-Based Adjuvants Vaccine Industry Opportunities and Challenges
  4. 2.4 Nanomaterial-Based Adjuvants Vaccine Industry Restraints
3 Nanomaterial-Based Adjuvants Vaccine Market by Manufacturers
  1. 3.1 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Nanomaterial-Based Adjuvants Vaccine Sales by Manufacturers (2021-2026)
  3. 3.3 Global Nanomaterial-Based Adjuvants Vaccine Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Nanomaterial-Based Adjuvants Vaccine Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Nanomaterial-Based Adjuvants Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Nanomaterial-Based Adjuvants Vaccine Manufacturers, Product Type & Application
  7. 3.7 Global Nanomaterial-Based Adjuvants Vaccine Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Nanomaterial-Based Adjuvants Vaccine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Nanomaterial-Based Adjuvants Vaccine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Nanomaterial-Based Adjuvants Vaccine Tier 1, Tier 2, and Tier 3
4 Nanomaterial-Based Adjuvants Vaccine Market by Type
  1. 4.1 Nanomaterial-Based Adjuvants Vaccine Type Introduction
  2. 4.1.1 Lipidosome
  3. 4.1.2 Aluminium Hydroxides
  4. 4.1.3 Aluminium Phosphate
  5. 4.1.4 Others
  6. 4.2 Global Nanomaterial-Based Adjuvants Vaccine Sales by Type
  7. 4.2.1 Global Nanomaterial-Based Adjuvants Vaccine Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Nanomaterial-Based Adjuvants Vaccine Sales by Type (2021-2032)
  9. 4.2.3 Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Type (2021-2032)
  10. 4.3 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Type
  11. 4.3.1 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Type (2021-2032)
  13. 4.3.3 Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Type (2021-2032)
5 Nanomaterial-Based Adjuvants Vaccine Market by Application
  1. 5.1 Nanomaterial-Based Adjuvants Vaccine Application Introduction
  2. 5.1.1 DTaP
  3. 5.1.2 Pneumococcus
  4. 5.1.3 Viral Hepatitis TypeA
  5. 5.1.4 Human Papilloma Virus
  6. 5.1.5 SARS-CoV-2
  7. 5.1.6 Viral Hepatitis TypeB
  8. 5.1.7 Others
  9. 5.2 Global Nanomaterial-Based Adjuvants Vaccine Sales by Application
  10. 5.2.1 Global Nanomaterial-Based Adjuvants Vaccine Sales by Application (2021 VS 2025 VS 2032)
  11. 5.2.2 Global Nanomaterial-Based Adjuvants Vaccine Sales by Application (2021-2032)
  12. 5.2.3 Global Nanomaterial-Based Adjuvants Vaccine Sales Market Share by Application (2021-2032)
  13. 5.3 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Application
  14. 5.3.1 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  15. 5.3.2 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Application (2021-2032)
  16. 5.3.3 Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Application (2021-2032)
6 Global Nanomaterial-Based Adjuvants Vaccine Sales by Region
  1. 6.1 Global Nanomaterial-Based Adjuvants Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Nanomaterial-Based Adjuvants Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Nanomaterial-Based Adjuvants Vaccine Sales by Region (2021-2026)
  4. 6.2.2 Global Nanomaterial-Based Adjuvants Vaccine Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Nanomaterial-Based Adjuvants Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Nanomaterial-Based Adjuvants Vaccine Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Nanomaterial-Based Adjuvants Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Nanomaterial-Based Adjuvants Vaccine Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Nanomaterial-Based Adjuvants Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Nanomaterial-Based Adjuvants Vaccine Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Region
  1. 7.1 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Region
  2. 7.1.1 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Region (2021-2026)
  4. 7.1.3 Global Nanomaterial-Based Adjuvants Vaccine Revenue by Region (2027-2032)
  5. 7.1.4 Global Nanomaterial-Based Adjuvants Vaccine Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Nanomaterial-Based Adjuvants Vaccine Revenue (2021-2032)
  8. 7.2.2 North America Nanomaterial-Based Adjuvants Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Nanomaterial-Based Adjuvants Vaccine Revenue (2021-2032)
  11. 7.3.2 Europe Nanomaterial-Based Adjuvants Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Nanomaterial-Based Adjuvants Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Nanomaterial-Based Adjuvants Vaccine Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Emergent BioSolutions
  2. 8.1.1 Emergent BioSolutions Company Information
  3. 8.1.2 Emergent BioSolutions Business Overview
  4. 8.1.3 Emergent BioSolutions Nanomaterial-Based Adjuvants Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Emergent BioSolutions Nanomaterial-Based Adjuvants Vaccine Product Portfolio
  6. 8.1.5 Emergent BioSolutions Recent Developments
  7. 8.2 GlaxoSmithKline Biologicals
  8. 8.2.1 GlaxoSmithKline Biologicals Company Information
  9. 8.2.2 GlaxoSmithKline Biologicals Business Overview
  10. 8.2.3 GlaxoSmithKline Biologicals Nanomaterial-Based Adjuvants Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 GlaxoSmithKline Biologicals Nanomaterial-Based Adjuvants Vaccine Product Portfolio
  12. 8.2.5 GlaxoSmithKline Biologicals Recent Developments
  13. 8.3 Moderna
  14. 8.3.1 Moderna Company Information
  15. 8.3.2 Moderna Business Overview
  16. 8.3.3 Moderna Nanomaterial-Based Adjuvants Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Moderna Nanomaterial-Based Adjuvants Vaccine Product Portfolio
  18. 8.3.5 Moderna Recent Developments
  19. 8.4 Pfizer
  20. 8.4.1 Pfizer Company Information
  21. 8.4.2 Pfizer Business Overview
  22. 8.4.3 Pfizer Nanomaterial-Based Adjuvants Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Nanomaterial-Based Adjuvants Vaccine Product Portfolio
  24. 8.4.5 Pfizer Recent Developments
  25. 8.5 Merck
  26. 8.5.1 Merck Company Information
  27. 8.5.2 Merck Business Overview
  28. 8.5.3 Merck Nanomaterial-Based Adjuvants Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Merck Nanomaterial-Based Adjuvants Vaccine Product Portfolio
  30. 8.5.5 Merck Recent Developments
  31. 8.6 Novartis
  32. 8.6.1 Novartis Company Information
  33. 8.6.2 Novartis Business Overview
  34. 8.6.3 Novartis Nanomaterial-Based Adjuvants Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Novartis Nanomaterial-Based Adjuvants Vaccine Product Portfolio
  36. 8.6.5 Novartis Recent Developments
  37. 8.7 Jiangsu Recbio Technology
  38. 8.7.1 Jiangsu Recbio Technology Company Information
  39. 8.7.2 Jiangsu Recbio Technology Business Overview
  40. 8.7.3 Jiangsu Recbio Technology Nanomaterial-Based Adjuvants Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Jiangsu Recbio Technology Nanomaterial-Based Adjuvants Vaccine Product Portfolio
  42. 8.7.5 Jiangsu Recbio Technology Recent Developments
  43. 8.8 Sanofi
  44. 8.8.1 Sanofi Company Information
  45. 8.8.2 Sanofi Business Overview
  46. 8.8.3 Sanofi Nanomaterial-Based Adjuvants Vaccine Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Sanofi Nanomaterial-Based Adjuvants Vaccine Product Portfolio
  48. 8.8.5 Sanofi Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Nanomaterial-Based Adjuvants Vaccine Value Chain Analysis
  2. 9.1.1 Nanomaterial-Based Adjuvants Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Nanomaterial-Based Adjuvants Vaccine Production Mode & Process
  6. 9.2 Nanomaterial-Based Adjuvants Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Nanomaterial-Based Adjuvants Vaccine Distributors
  9. 9.2.3 Nanomaterial-Based Adjuvants Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst